Biogen's Aducanumab Advisory Committee Will Test US FDA's 'Substantial Evidence' Flexibility

 
• By Sue Sutter
Hands_Alzheimers_Awareness
An FDA panel will consider whether aducanumab should be the first disease-modifying treatment approved for Alzheimer’s • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers